Fifth Third Wealth Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Fifth Third Wealth Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$480K	Sell	1,994 -2	-0.1%	-$438	0.01%	506
2026 Q1	$377K	Buy	1,996 +85	+4%	+$14.9K	0.01%	521
2025 Q4	$325K	Sell	1,911 -40	-2%	-$6.13K	0.01%	551
2025 Q3	$257K	Buy	1,951 +44	+2%	+$5.28K	0.01%	621
2025 Q2	$202K	Buy	1,907 +5	+0.3%	+$543	0.01%	722
2025 Q1	$236K	Buy	1,902 +6	+0.3%	+$783	0.01%	599
2024 Q4	$233K	Sell	1,896 -33	-2%	-$3.89K	0.01%	618
2024 Q3	$215K	Sell	1,929 -5	-0.3%	-$548	0.01%	627
2024 Q2	$206K	Buy	+1,934	New	+$213K	0.02%	591

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Fifth Third Wealth Advisors's JAZZ Position: Q2 2026 in Review

Fifth Third Wealth Advisors reduced its Jazz Pharmaceuticals (JAZZ) stake by 0.1% in Q2 2026, selling an estimated $438 and leaving 1,994 shares worth $480K. The position accounts for 0.01% of the portfolio, ranked #506.

Fifth Third Wealth Advisors first reported a position in JAZZ in Q2 2024 and has held it in 9 quarters since. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Fifth Third Wealth Advisors held 1,994 shares of Jazz Pharmaceuticals worth $480K as of Q2 2026.
Fifth Third Wealth Advisors sold 2 Jazz Pharmaceuticals shares in Q2 2026, an estimated $438.
Jazz Pharmaceuticals made up 0.01% of Fifth Third Wealth Advisors's portfolio in Q2 2026, its #506 holding.
Fifth Third Wealth Advisors first reported a position in Jazz Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Fifth Third Wealth Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.